NASDAQ:CERC Cerecor Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cerecor Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.29 -0.14 (-5.76 %) (As of 09/28/2020 12:00 AM ET) Add Compare Share Today's Range$2.26Now: $2.29▼$2.4550-Day Range$2.20MA: $2.55▼$2.8652-Week Range$1.52Now: $2.29▼$6.19Volume195,767 shsAverage Volume377,272 shsMarket Capitalization$171.52 millionP/E RatioN/ADividend YieldN/ABeta1.69 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Cerecor Inc., a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device. The company is developing CERC-301, an orphan neurological indication for controlling neurologic adaptation; CERC-406 for the treatment of Parkinson's disease; CERC-425, an orally active small molecule; CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy; and CERC-913, a protide nucleotide for the treatment of mitochondrial disorder. It also developing preclinical therapies CERC-801, CERC-802, and CERC-803 for the treatment of inherited metabolic disorders. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingCerecor has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, Cerecor has a forecasted upside of 358.5% from its current price of $2.29.Amount of Analyst CoverageCerecor has received no research coverage in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesCerecor has received 178 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCerecor has received 131 “underperform” votes. (Add your “underperform” vote.)Community SentimentCerecor has received 57.61% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cerecor and other stocks. Vote “Outperform” if you believe CERC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CERC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCerecor does not currently pay a dividend.Dividend GrowthCerecor does not have a long track record of dividend growth. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerecor insiders have bought more of their company's stock than they have sold. Specifically, they have bought $220,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders58.00% of the stock of Cerecor is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.20% of the stock of Cerecor is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cerecor are expected to decrease in the coming year, from ($0.43) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerecor is -7.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerecor is -7.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerecor has a P/B Ratio of 5.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.26 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CERC Previous Symbol CUSIPN/A CIK1534120 Webwww.cerecor.com Phone410-522-8707Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio3.44Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.75 million Price / Sales25.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book5.73Profitability EPS (Most Recent Fiscal Year)($0.30) Net Income$-16,070,000.00 Net MarginsN/A Return on Equity-74.50% Return on Assets-41.60%Miscellaneous Employees64 Outstanding Shares74,900,000Market Cap$171.52 million Next Earnings Date11/12/2020 (Estimated) OptionableOptionable $2.29 -0.14 (-5.76 %) (As of 09/28/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CERC News and Ratings via Email Sign-up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter. Cerecor (NASDAQ:CERC) Frequently Asked Questions How has Cerecor's stock been impacted by COVID-19? Cerecor's stock was trading at $2.41 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CERC stock has decreased by 5.0% and is now trading at $2.29. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Cerecor? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerecor in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cerecor. When is Cerecor's next earnings date? Cerecor is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020. View our earnings forecast for Cerecor. How were Cerecor's earnings last quarter? Cerecor Inc (NASDAQ:CERC) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.05. The business had revenue of $1.34 million for the quarter, compared to the consensus estimate of $2.25 million. View Cerecor's earnings history. What price target have analysts set for CERC? 4 equities research analysts have issued 12-month price targets for Cerecor's shares. Their forecasts range from $10.00 to $12.00. On average, they anticipate Cerecor's stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 358.5% from the stock's current price. View analysts' price targets for Cerecor. Are investors shorting Cerecor? Cerecor saw a increase in short interest in September. As of September 15th, there was short interest totaling 1,460,000 shares, an increase of 12.3% from the August 31st total of 1,300,000 shares. Based on an average daily trading volume, of 588,300 shares, the short-interest ratio is presently 2.5 days. View Cerecor's Short Interest. Who are some of Cerecor's key competitors? Some companies that are related to Cerecor include VBI Vaccines (VBIV), Emisphere Technologies (EMIS), Frequency Therapeutics (FREQ), Collegium Pharmaceutical (COLL), Kadmon (KDMN), DiaMedica Therapeutics (DMCAF), ImmunoGen (IMGN), Spectrum Pharmaceuticals (SPPI), Northwest Biotherapeutics (NWBO), Basilea Pharmaceutica (BPMUF), ORIC Pharmaceuticals (ORIC), Cara Therapeutics (CARA), Legend Biotech (CALT), Axovant Sciences (AXON) and Forte Biosciences (FBRX). View all competitors. What other stocks do shareholders of Cerecor own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerecor investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), BioNano Genomics (BNGO), Gran Tierra Energy (GTE), KushCo (KSHB), AEterna Zentaris (AEZS), Novan (NOVN), Zosano Pharma (ZSAN), OrganiGram (OGI) and Pennsylvania R.E.I.T. (PEI). Who are Cerecor's key executives? Cerecor's management team includes the following people: Ms. Mariam E. Morris, Consultant (Age 51)Dr. Simon C. Pedder Ph.D., Exec. Chairman (Age 58)Mr. Joseph M. Miller CPA, Chief Financial Officer (Age 45)Dr. Solomon H. Snyder, Founder and Chairman of Scientific Advisory Board (Age 80)Dr. Barbara S. Slusher, Founder and Member of Scientific Advisory Board (Age 54) What is Cerecor's stock symbol? Cerecor trades on the NASDAQ under the ticker symbol "CERC." Who are Cerecor's major shareholders? Cerecor's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (7.59%), Opaleye Management Inc. (4.50%), Ikarian Capital LLC (0.54%), Nuveen Asset Management LLC (0.21%), Goldman Sachs Group Inc. (0.19%) and Assenagon Asset Management S.A. (0.19%). Company insiders that own Cerecor stock include Armistice Capital Master Fund, Armistice Capital, Llc, Cerecor Inc, Christopher Ryan Sullivan, James Archie Harrell Jr, Joseph M Miller, Matthew V Phillips, Michael F Cola, Pericles Calias and Simon Pedder. View institutional ownership trends for Cerecor. Which major investors are selling Cerecor stock? CERC stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, and UBS Group AG. View insider buying and selling activity for Cerecor. Which major investors are buying Cerecor stock? CERC stock was purchased by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Opaleye Management Inc., Goldman Sachs Group Inc., Assenagon Asset Management S.A., Nuveen Asset Management LLC, Two Sigma Advisers LP, Bank of New York Mellon Corp, and Jane Street Group LLC. Company insiders that have bought Cerecor stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc, Christopher Ryan Sullivan, James Archie Harrell Jr, Joseph M Miller, Matthew V Phillips, Michael F Cola, Pericles Calias, and Simon Pedder. View insider buying and selling activity for Cerecor. How do I buy shares of Cerecor? Shares of CERC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cerecor's stock price today? One share of CERC stock can currently be purchased for approximately $2.29. How big of a company is Cerecor? Cerecor has a market capitalization of $171.52 million and generates $6.75 million in revenue each year. The company earns $-16,070,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis. Cerecor employs 64 workers across the globe. What is Cerecor's official website? The official website for Cerecor is www.cerecor.com. How can I contact Cerecor? Cerecor's mailing address is 540 Gaither Road Suite 400, Rockville MD, 20850. The company can be reached via phone at 410-522-8707 or via email at [email protected] This page was last updated on 9/28/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
